(Q39407871)

English

Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1.

scientific article published on March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. (English)

1 reference

Europe PubMed Central

11 September 2017

Epstein–Barr virus

0 references

membrane protein

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

author name string

Joo Hyun Kim

1

1 reference

Europe PubMed Central

11 September 2017

Won Seog Kim

2

1 reference

Europe PubMed Central

11 September 2017

Chaehwa Park

3

1 reference

Europe PubMed Central

11 September 2017

publication date

1 March 2012

1 reference

Europe PubMed Central

11 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

11 September 2017

53

1 reference

Europe PubMed Central

11 September 2017

8

1 reference

Europe PubMed Central

11 September 2017

1586-1591

1 reference

Europe PubMed Central

11 September 2017

The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.659736

21 January 2018

Identifiers

10.3109/10428194.2012.659736

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39407871&oldid=1525215267"